

Data Sheet


WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

 $\begin{tabular}{lll} \textbf{Product Name} & :PDZ1i \\ \textbf{Cat.No.} & :URK-V2231 \\ \textbf{CAS No.} & :2083618-79-3 \\ \textbf{Molecular Formula} & :C_{28}H_{26}N_8O \\ \end{tabular}$

Molecular Weight :538.568
Target :

Target : Solubility :



Biological Activity

PDZ1i (113B7) is a specific inhibitor of MDA-9/Syntenin activity that inhibits MDA-9/Syntenin binding to EGFRvIII. PDZ1i (113B7) selectively binds with micromolar affinity to the PDZ1 domain of MDA-9/Syntenin, with no affinity for PDZ2 domain of MDA-9/Syntenin.

PDZ1i (113B7) reduces invasion gains in GBM cells following radiation, inhibits crucial GBM signaling involving FAK and mutant EGFR, EGFRvIII, and abrogated gains in secreted proteases, MMP-2 and MMP-9, following radiation. PDZ1i (113B7) treatment results in smaller, less invasive tumors and enhanced survival in an in vivo glioma model.

References

1. Kegelman TP, et al. Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):370-375.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!